Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 4:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Omeros Corporation Clear all
Completed Phase 2Phase 3 Interventional

Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP With Vehicle Irrigation Solution in Subjects Undergoing Meniscectomy

NCT00624845
View directory record Official record
Conditions
Postoperative Pain
Interventions
OMS103HP, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 3, 2026, 4:20 PM EDT
Terminated Phase 2 Interventional Results available

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

NCT02682407
View directory record Official record
Conditions
IgAN, LN, MN, C3G
Interventions
OMS721 (narsoplimab)
Biological
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Denver, Colorado • Augusta, Georgia • Lawrenceville, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 3, 2026, 4:20 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of OMS103HP in Patients Undergoing Allograft Anterior Cruciate Ligament (ACL) Reconstruction

NCT00226759
View directory record Official record
Conditions
Knee Injuries
Interventions
OMS103HP, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
15 Years to 65 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
18
States / cities
Encinitas, California • Redwood City, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 3, 2026, 4:20 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) Reconstruction

NCT00226772
View directory record Official record
Conditions
Knee Injuries
Interventions
OMS103HP, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
15 Years to 65 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
15
States / cities
Encinitas, California • Denver, Colorado • Englewood, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 3, 2026, 4:20 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome

NCT03205995
View directory record Official record
Conditions
Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome
Interventions
OMS721 (narsoplimab)
Biological
Lead sponsor
Omeros Corporation
Industry
Eligibility
12 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 3, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

NCT01579565
View directory record Official record
Conditions
Intraocular Lens Replacement
Interventions
OMS302, Placebo
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Chandler, Arizona • Los Angeles, California • Fort Myers, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 3, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Results available

A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement

NCT02132312
View directory record Official record
Conditions
Unilateral Cataract Extraction, Congenital Cataract
Interventions
OMS302, Phenylephrine HCl
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
1 Day to 47 Months
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 3, 2026, 4:20 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Pioglitazone for Heroin and for Nicotine Dependence

NCT01395797
View directory record Official record
Conditions
Heroin Dependence, Nicotine Dependence
Interventions
PIO, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 3, 2026, 4:20 PM EDT
Completed Phase 1Phase 2 Interventional

Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.

NCT00721695
View directory record Official record
Conditions
Cataract Extraction
Interventions
OMS302, OMS302-PE, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Redding, California • Bloomington, Minnesota • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2014 · Synced Oct 3, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

NCT01454063
View directory record Official record
Conditions
Intraocular Lens Replacement
Interventions
OMS302, Placebo
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
16
States / cities
Chandler, Arizona • Glendale, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 3, 2026, 4:20 PM EDT
Completed Phase 3 Interventional

Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction

NCT00245271
View directory record Official record
Conditions
Anterior Cruciate Ligament Reconstruction
Interventions
OMS103HP, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
17 Years to 65 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
10
States / cities
Los Angeles, California • Redwood City, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 3, 2026, 4:20 PM EDT
Completed Phase 4 Interventional Results available

No Drop Post-Op Cataract Surgery

NCT03864133
View directory record Official record
Conditions
Cataract
Interventions
Omidria
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 90 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 3, 2026, 4:20 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects

NCT01952132
View directory record Official record
Conditions
Schizophrenia
Interventions
OMS643762, Placebo
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 3, 2026, 4:20 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Safety Study of OMS201 in Subjects Undergoing Ureteroscopic Treatment for Removal of Urinary Tract-Located Stones

NCT00599664
View directory record Official record
Conditions
Urinary Calculi, Urinary Stones, Urinary Tract Stones
Interventions
OMS201, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Orange, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2010 · Synced Oct 3, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies

NCT02222545
View directory record Official record
Conditions
Thrombotic Microangiopathies
Interventions
OMS721
Biological
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Duarte, California • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 3, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)

NCT01193127
View directory record Official record
Conditions
Cataract
Interventions
OMS302 Solution, OMS302 Mydriatic Solution, OMS302 Anti-inflammatory Solution, Balanced Salt Solution (BSS) Solution
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Chandler, Arizona • Glendale, Arizona • Little Rock, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Oct 3, 2026, 4:20 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease

NCT02074410
View directory record Official record
Conditions
Huntington's Disease
Interventions
OMS643762, Placebo
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
San Diego, California • Englewood, Colorado • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 3, 2026, 4:20 PM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

NCT05855083
View directory record Official record
Conditions
Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
Interventions
Biological: narsoplimab
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
28 Days to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
San Diego, California • Gainesville, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 3, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone

NCT01395784
View directory record Official record
Conditions
Opioid Abuse
Interventions
pioglitazone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 3, 2026, 4:20 PM EDT
Terminated Phase 3 Interventional Results available

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

NCT03608033
View directory record Official record
Conditions
IgA Nephropathy
Interventions
OMS721, Vehicle (D5W or saline)
Biological · Other
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
34
States / cities
Florence, Alabama • Mesa, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 3, 2026, 4:20 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy

NCT01406561
View directory record Official record
Conditions
Meniscal Tear
Interventions
OMS103HP-S, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Encinitas, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 3, 2026, 4:20 PM EDT
Completed Phase 1Phase 2 Interventional

Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones

NCT00857090
View directory record Official record
Conditions
Urinary Calculi, Urinary Stones, Urinary Tract Stones, Renal Calculi, Kidney Stones
Interventions
OMS201, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Orange, California • Denver, Colorado • Nasville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 3, 2026, 4:20 PM EDT